Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Durom Hip Resurfacing System · 1 trial · 1 indication
| Name | Type | Description |
|---|---|---|
| Durom Hip Resurfacing System | DEVICE | Hip resurfacing devices in the young, active patient with advanced hip disease instead of traditional total hip arthroplasty. |
Top 20 of 24 competitors
The Durom Hip Resurfacing System is used for advanced hip disease. It is a hip resurfacing system designed to treat patients with this condition. The device is currently in clinical development and is not approved by the FDA.
The Durom Hip Resurfacing System is developed by Zimmer Biomet Holdings, Inc., which trades under the ticker symbol ZBH. The company is conducting clinical trials to evaluate the safety and effectiveness of this hip resurfacing system.
The Durom Hip Resurfacing System is in Phase 3 clinical development. It is an investigational device and has not received FDA approval. One Phase 3 trial has been completed as part of its clinical evaluation.
The Durom Hip Resurfacing System has one completed Phase 3 clinical trial, identified as NCT00746616, titled 'Durom(R) Hip Resurfacing System Multicenter Trial.' This trial enrolled 40 patients with advanced hip disease and was uncontrolled, meaning it did not use a control group.
The Durom Hip Resurfacing System is not FDA approved. It is an investigational device currently in Phase 3 clinical development. The completed trial, NCT00746616, evaluated its use in patients with advanced hip disease, but regulatory approval has not been granted.